From CURE Epilepsy <[email protected]>
Subject Epilepsy Research News: August 2023
Date August 10, 2023 8:00 PM
  Links have been removed from this email. Learn more in the FAQ.
  Links have been removed from this email. Learn more in the FAQ.
See the latest research on epilepsy, post-traumatic epilepsy (PTE), and more.

View this email in your browser ([link removed])

CURE Epilepsy is dedicated to funding patient-focused research to find a cure for the 65 million people with epilepsy worldwide. This month, we share the following articles and abstracts which are furthering the study of epilepsy and bringing the world closer to a cure.

This issue of Epilepsy Research News includes summaries of articles on:
* Brain Changes Associated with the Development of Post-Traumatic Epilepsy (PTE) ([link removed])
* A New Brain Circuit Important in Epilepsy ([link removed])
* MicroRNA as a Target to Treat Epilepsy ([link removed])
* Fetal Exposure to Antiseizure Medications and Long-Term Neurodevelopment in Children ([link removed])



** Brain Changes Associated with the Development of
------------------------------------------------------------


** Post-Traumatic Epilepsy (PTE)
------------------------------------------------------------

Research from the CURE Epilepsy PTE Initiative ([link removed]) team at Virginia Tech has identified several changes in the brain that are associated with the development of PTE after a traumatic brain injury (TBI). The team examined changes in brain activity, cellular changes, and changes in the number of neurons in the brain after the development of PTE. The team found significant cellular and molecular changes in the dentate gyrus of the hippocampus, an area of the brain that has been implicated in seizure development. For example, the team found significant loss of neurons that inhibit brain activity, which may be important because seizures involve too much brain excitation, as well as changes in the structure of astroglia, which are cells that help regulate the transmission of signals between neurons in the brain. These findings suggest that changes in the dentate gyrus may contribute to the development of PTE following TBI.

Learn More ([link removed])


** A New Brain Circuit Important in Epilepsy
------------------------------------------------------------

Researchers have traced brain lesions (for example those caused by stroke, trauma, and tumors) that are associated with epilepsy to a shared brain circuit, indicating a unique role that deep brain circuits play in the origin and clinical management of epilepsy. The researchers found that lesions associated with epilepsy were connected to a common brain network located deep within the brain in regions called the basal ganglia and cerebellum. The researchers also examined a group of 30 individuals with drug-resistant epilepsy who underwent deep brain stimulation (DBS) to treat seizures and found that the individuals did better if the DBS site was connected to the same brain network implicated for epilepsy caused by brain lesions. The authors conclude that a lesion-related epilepsy network map could help identify patients at risk of epilepsy after a brain lesion and guide brain stimulation therapies.

Learn More ([link removed])


** MicroRNA as a Target to Treat Epilepsy
------------------------------------------------------------

A recent study featuring the work of former CURE Epilepsy grantee Dr. David Henshall ([link removed]) and colleagues investigated the role of the brain molecule micro-ribonucleic acid (miRNA) miR-335-5p as a potential therapeutic target for epilepsy. miRNAs can control levels of voltage-gated sodium channels, which are important in neuronal excitability, making them an attractive target of new treatments. Additionally, voltage-gated sodium channel function is decreased in some forms of epilepsy, like Dravet syndrome. The researchers found that miR-335-5p regulates voltage-gated sodium channels' levels and neuronal excitability, supporting a role in epilepsy. The researchers concluded that targeting miR-335-5p could potentially lead to new treatments for epilepsy through its ability to influence voltage-gated sodium channels and neuronal excitability.

Learn More ([link removed])


** Fetal Exposure to Antiseizure Medications and Long-Term Neurodevelopment in Children
------------------------------------------------------------

A new study found that young children who were exposed to commonly prescribed antiseizure medications in utero do not score worse on several long-term neurodevelopmental outcomes (at age three) than children who were not exposed. This study recruited women who were treated for epilepsy at 20 medical centers across the United States and followed them and their babies over the course of pregnancy and several years postpartum. To assess the effects of fetal exposure to medications, children were tested for their vocabulary and verbal comprehension skills at the age of three. Children of women with epilepsy were as good at verbally describing simple objects and pictures as children of women without epilepsy, and their ability to understand language was also comparable. The researchers did find that a high dosage of levetiracetam (Keppra®) in the third trimester of pregnancy was correlated with certain negative neurodevelopmental effects in children and recommend especially careful monitoring of
blood levels of this drug and thoughtful dosing strategies.

Learn More ([link removed])
[link removed] [link removed] [link removed] [link removed] [link removed] [link removed]
[link removed]

Today's research has the ability to help
the 65 million people worldwide who are impacted by epilepsy every day.
And each one of those individuals has a story.
Read Anu's story ([link removed])
[link removed]

Our mission is to find a cure for epilepsy, by promoting and funding patient-focused research.

CURE Epilepsy is a non-profit 501(c)(3) tax-exempt organization. Our tax identification number is 36-4253176.

Copyright (C) 2023 CURE Epilepsy. All rights reserved.
In the past you provided CURE Epilepsy your email address. Occasionally, you will receive updates from us about epilepsy research and news.
Our mailing address is:
CURE Epilepsy
420 Wabash Ave, Ste 650
Chicago, IL 60611
USA
Want to change how you receive these emails?
You can update your preferences ([link removed]) or unsubscribe ([link removed])

This email was sent to [email protected] (mailto:[email protected])
why did I get this? ([link removed]) unsubscribe from this list ([link removed]) update subscription preferences ([link removed])
CURE Epilepsy . 420 Wabash Ave, Ste 650 . Chicago, IL 60611 . USA
Screenshot of the email generated on import

Message Analysis